Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UPV9
UPID:
TRAK1_HUMAN
Alternative names:
106 kDa O-GlcNAc transferase-interacting protein; Protein Milton
Alternative UPACC:
Q9UPV9; E9PDS2; J3KNT7; Q63HR0; Q659B5; Q96B69
Background:
Trafficking kinesin-binding protein 1, also known as Protein Milton and 106 kDa O-GlcNAc transferase-interacting protein, plays a pivotal role in cellular processes. It regulates endosome-to-lysosome trafficking, including the endocytic trafficking of EGF-EGFR complexes and GABA-A receptors. Additionally, it is involved in mitochondrial motility and recruits OGT to the mitochondrial surface in neuronal processes.
Therapeutic significance:
The protein's association with Developmental and epileptic encephalopathy 68, a severe early-onset epilepsy, underscores its therapeutic significance. Understanding the role of Trafficking kinesin-binding protein 1 could lead to novel therapeutic strategies for managing this debilitating condition.